Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix (NBTX) reported complete Phase 1 full-cohort results for radiotherapy-activated JNJ-1900 (NBTXR3) in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation.
All 24 patients completed JNJ-1900 plus re-irradiation with no dose-limiting toxicities and no Grade 3 or higher adverse events related to JNJ-1900 or the injection procedure. Grade 3 radiotherapy-related adverse events occurred in 33% of patients and Grade 5 radiotherapy-related events in 8%. The recommended Phase 2 dose was set at 33% of gross tumor volume.
At a median 12‑month follow-up (data cutoff August 2026), one-year locoregional control was 79%, one-year local progression-free survival was 61% (median 13.6 months), and one-year overall survival was 70% (median 14.8 months). Investigators concluded that JNJ-1900 may enable clinically meaningful local control at substantially lower re-irradiation doses, and additional enrollment in this trial is planned.
Nanobiotix (NBTX) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 12:00 pm EDT (6:00 pm CEST) in New York, NY.
The session will feature Chief Executive Officer Laurent Lévy and Chief Financial and Business Officer Bart Van Rhijn. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, listed on Euronext Paris and the Nasdaq Global Select Market, and focused on physics-based therapeutic approaches across oncology, bioavailability and biodistribution, and central nervous system disorders. The company holds more than 30 umbrella patents covering three nanotechnology platforms.
Nanobiotix (Euronext Paris, Nasdaq: NBTX) published its monthly disclosure of share capital and voting rights in line with French regulatory requirements. As of July 31, 2026, the company reports 50,833,462 shares outstanding.
Total voting rights amount to 54,534,179 theoretical (“gross”) and 54,512,061 exercisable (“net”) voting rights. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, focused on physics-based therapeutic approaches in oncology and other indications.
Nanobiotix (Euronext Paris / Nasdaq: NBTX) reported its share capital and voting rights as of June 30, 2026, in accordance with French regulations (articles L.233-8 II of the French Commercial Code and 223-16 of the AMF General Regulation).
According to Nanobiotix, the company had 50,825,682 shares outstanding, corresponding to 54,486,890 theoretical (gross) voting rights and 54,464,772 exercisable (net) voting rights. The theoretical voting rights figure includes shares with suspended rights, while the exercisable voting rights exclude shares held in treasury.
Nanobiotix (Nasdaq: NBTX) reported its share capital and voting rights as of May 31, 2026, in line with French market regulations.
The company had 50,807,903 shares outstanding, with 54,304,858 theoretical and 54,282,740 exercisable voting rights on Euronext Paris and Nasdaq.
Nanobiotix (NASDAQ:NBTX) reported Q1 2026 operational and financial updates, highlighting clinical, preclinical, and financing progress.
The company completed a €86.1 million follow-on offering, reported encouraging early JNJ-1900 (NBTXR3) Phase 2 NSCLC data, amended the NANORAY-312 Phase 3 protocol, shared new Nanoprimer preclinical results, and held €42.1 million in cash, supporting operations into 2029.
Nanobiotix (NASDAQ:NBTX), a late-clinical stage biotechnology company, has been added to the Euronext Tech Leaders segment and Euronext Tech Leaders Index as of June 2, 2026.
This inclusion highlights its physics-based nanotherapeutic platforms and may enhance visibility with international technology-focused investors.
Nanobiotix (NASDAQ:NBTX) closed its global offering, including full exercise of underwriters’ option, raising approximately $100 million (€86.1 million) in gross proceeds. The deal comprised 2,218,467 ordinary shares (including ADSs and Additional ADSs) and 345,099 pre-funded warrants at a subscription price of €33.60 per share.
According to the company, net proceeds plus existing cash are expected to fund operations into 2029, mainly supporting Nanoprimer and other platforms, JNJ-1900 (NBTXR3) development, and general corporate purposes.
Nanobiotix (NASDAQ:NBTX) announced that underwriters fully exercised their over-allotment option to buy 33,805 additional ADSs at $38.98, bringing total Global Offering gross proceeds to about $100 million (€86.1 million), before fees.
The deal covers 2,218,467 ordinary shares and 345,099 pre-funded warrants. Nanobiotix plans to allocate less than 10% of net proceeds to JNJ-1900 (NBTXR3), 50–60% to Nanoprimer and other platforms, and 30–40% to general corporate purposes, supporting operations into 2029.
Nanobiotix (NASDAQ:NBTX) priced an oversubscribed global follow-on offering of 225,373 ADSs in the U.S. and 1,959,289 ordinary shares plus 345,099 pre-funded warrants in Europe, raising expected gross proceeds of about $98.6 million (€85.0 million), excluding any over-allotment.
The company plans to allocate 50–60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30–40% to general corporate purposes, and expects funding to support operations into 2029.